Pfizer and biontech announce data demonstrating high immune response following a booster dose of their covid-19 vaccine in children 5 through 11 years of age

New york & mainz, germany--(business wire)--pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced positive results from a phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-Μg booster (third) dose of the pfizer-biontech covid-19 vaccine in healthy children 5 through 11 years of age. these data demonstrate an increase in sars-cov-2 omicron variant and wild-type strain neutralizing titers following a booster dose of the pfizer-biontech covid-1
BNTX Ratings Summary
BNTX Quant Ranking